Login to Your Account



Probiodrug Gets €36M for Novel Alzheimer's Program

By Cormac Sheridan


Wednesday, November 4, 2009

In what could well be Europe's largest venture capital investment in biotechnology this year, Probiodrug AG took in more than €36 million (US$53.4 million) in a Series B round to fund a new class of Alzheimer's disease drugs, based on inhibiting glutaminyl cyclase (QC). The company also will allocate part of the proceeds to developing compounds acting on the same target for treating inflammatory indications. (BioWorld International)

 

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription